Literature DB >> 22318884

Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry.

Xilin Yang1, Wing-Yee So, Ronald C W Ma, Alice P S Kong, Gang Xu, Juliana C N Chan.   

Abstract

Diabetes is a disorder of energy metabolism associated with increased cancer risk, but the underlying mechanism is poorly understood. In a prospective cohort of patients enrolled in the Hong Kong Diabetes Registry, we explored risk factors for cancer including drug usage in type 2 diabetes. In a series of published papers, we reported a linear risk association of cancer with glycated haemoglobin with a threshold at 6.0%-6.5% and non-linear risk associations of body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride and white blood cell (WBC) count in V-shaped or A-shaped manners. Detailed pharmacoepidemiological analysis revealed markedly attenuated cancer risk in patients treated with insulin and oral anti-diabetic drugs compared with non-users of these drugs. We further observed significant drug-subphenotype interactions with attenuated cancer risk in metformin users with low high-density lipoprotein cholesterol, renin-angiotensin system (RAS) inhibitor users with high WBC count and statin users with co-presence of low low-density lipoprotein cholesterol plus albuminuria or low triglyceride. These novel observations corroborate with experimental findings of possible consequences of hyperglycaemia on dysregulation of cholesterol metabolism, renin-angiotensin system and adenosine 5'-monophosphate-activated protein kinase pathways, all of which may be implicated in carcinogenesis. On the basis of these epidemiological and experimental findings, we argue for the strong need to strengthen the health care system to ensure that type 2 diabetes subjects receive appropriate drugs to optimize internal milieu to reduce all events including cancer. Apart from mechanistic studies, large-scale, randomized clinical trials using medications such as statin, renin-angiotensin system inhibitors and metformin in patients with risk-conferring subphenotypes are needed to confirm their anti-cancer effects.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318884     DOI: 10.1002/dmrr.2287

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  18 in total

1.  Diabetes, insulin and cancer risk.

Authors:  Xi-Lin Yang; Juliana Cn Chan
Journal:  World J Diabetes       Date:  2012-04-15

2.  Cancer risk in type 2 diabetes.

Authors:  Alice P S Kong; Juliana C N Chan
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

3.  Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives.

Authors:  Xilin Yang; Juliana Cn Chan
Journal:  Ann Transl Med       Date:  2014-06

4.  Legacy effect of high glucose on promoting survival of HCT116 colorectal cancer cells by reducing endoplasmic reticulum stress response.

Authors:  Heung Man Lee; Shao Chin Lee; Lan He; Alice Pik Shan Kong; Dandan Mao; Yong Hou; Arthur Chi Kong Chung; Gang Xu; Ronald Ching Wan Ma; Juliana Chung Ngor Chan
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 5.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

6.  Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis.

Authors:  Zhida Wang; Cuiping Bao; Cheng Su; Weili Xu; Hongbin Luo; Liming Chen; Xiuying Qi
Journal:  J Diabetes Investig       Date:  2013-07-15       Impact factor: 4.232

7.  Hyperglycemia and blood pressure treatment goal: a cross sectional survey of 18350 patients with type 2 diabetes in 77 tertiary hospitals in China.

Authors:  Linong Ji; Xinyue Zhi; Juming Lu; Xiaohui Guo; Wenying Yang; Weiping Jia; Dajin Zou; Zhiguang Zhou; Qiuhe Ji; Dalong Zhu; Lixin Shi; Jianping Weng
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

8.  Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry.

Authors:  Alice P S Kong; Xilin Yang; Andrea Luk; Kitty K T Cheung; Ronald C W Ma; Wing Yee So; Chung Shun Ho; Michael H M Chan; Risa Ozaki; Chun Chung Chow; Nicola Brown; Juliana C N Chan
Journal:  BMC Endocr Disord       Date:  2014-06-13       Impact factor: 2.763

9.  Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China.

Authors:  Yunjuan Gu; Xuhong Hou; Ying Zheng; Chunfang Wang; Lei Zhang; Jie Li; Zhezhou Huang; Ming Han; Yuqian Bao; Weijian Zhong; Weiping Jia; Shiwei Cui
Journal:  Int J Environ Res Public Health       Date:  2016-06-03       Impact factor: 3.390

10.  Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.

Authors:  Alice P S Kong; Xilin Yang; Wing-Yee So; Andrea Luk; Ronald C W Ma; Risa Ozaki; Kitty K T Cheung; Heung-Man Lee; Linda Yu; Gang Xu; Chun-Chung Chow; Juliana C N Chan
Journal:  BMC Med       Date:  2014-05-13       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.